Today: 1 May 2026
Browse Category

Rocket Lab 22 January 2026 - 21 April 2026

Why Rocket Lab Stock Is Rising Again as Analysts Lift Targets and Golden Dome Spending Comes Into Focus

Why Rocket Lab Stock Is Rising Again as Analysts Lift Targets and Golden Dome Spending Comes Into Focus

Rocket Lab shares rose 2% to $91.12 Tuesday after analysts raised price targets and the Pentagon detailed new space defense spending in its 2027 budget request. The company closed its $155 million Mynaric acquisition last week and reported a $190 million Pentagon launch contract in March, bringing its backlog above $2 billion. Rocket Lab now expects to launch its Neutron rocket in late 2026 after a test setback.
Rocket Lab Stock Jumps as Mynaric Deal, Gauss Thruster Fuel Fresh Bullish Calls

Rocket Lab Stock Jumps as Mynaric Deal, Gauss Thruster Fuel Fresh Bullish Calls

Rocket Lab shares rose 9% Thursday after launching a new electric satellite thruster and closing its $155.3 million acquisition of Mynaric. Shares traded at $80.39 by 11:30 a.m. EDT. The company reported $602 million in 2025 revenue and a $1.85 billion backlog. Rocket Lab delayed its Neutron rocket to late 2026 after a tank test failure.
SpaceX IPO Buzz Puts Rocket Lab, Planet Labs and 3 Other Space Stocks in Focus

SpaceX IPO Buzz Puts Rocket Lab, Planet Labs and 3 Other Space Stocks in Focus

Planet Labs jumped 16.9% in premarket trading Monday, leading gains among U.S.-listed space stocks as investors sought public alternatives to SpaceX ahead of its expected IPO. Rocket Lab rose 3.3%, Viasat 18.7%, BlackSky 11.5%, and Redwire 7.2%. SpaceX’s confidential IPO filing and talks with Saudi Arabia’s Public Investment Fund have intensified focus on sector peers.
Rocket Lab stock price swings as $1 billion share-sale filing dents rally

Rocket Lab stock price swings as $1 billion share-sale filing dents rally

Rocket Lab shares fell more than 5% after hours Tuesday following a filing to sell up to $1 billion in stock through an at-the-market program and forward sale agreements. The company ended 2025 with $1.1 billion in cash and is ending a prior $750 million stock-sale program. Rocket Lab reported record 2025 revenue but delayed the first Neutron rocket launch to late 2026 after a tank test failure.
Rocket Lab stock price drops 5% as space stocks slide; hypersonic test and Feb. 26 earnings loom

Rocket Lab stock price drops 5% as space stocks slide; hypersonic test and Feb. 26 earnings loom

Rocket Lab shares closed down 5.2% at $66.01 Thursday, extending an 8% three-day slide as space stocks fell after AST SpaceMobile’s $1 billion debt deal. The company flagged a late-February hypersonic test for the U.S. Defense Innovation Unit and will report results Feb. 26, with investors awaiting updates on its Neutron rocket schedule.
Rocket Lab stock slides again; RKLB ends down 9% as investors eye earnings and Washington risk

Rocket Lab stock slides again; RKLB ends down 9% as investors eye earnings and Washington risk

Rocket Lab shares fell 9.3% to $66.32 Thursday, then slid another 6% after hours, extending losses to 18% since Tuesday. The drop followed two sharp sell-offs after a brief rally tied to SpaceX-xAI news and was compounded by Congress rejecting NASA Mars mission funding. Investors now await Rocket Lab’s earnings report on Feb. 26.
Rocket Lab stock slides again as RKLB pulls back from January highs

Rocket Lab stock slides again as RKLB pulls back from January highs

Rocket Lab shares fell 5.35% to $75.79 by Monday afternoon, extending losses to 24% below their January high. The drop follows reports that Congress pulled funding for NASA’s Mars Sample Return mission, for which Rocket Lab had proposed a $4 billion role. Investors remain focused on the company’s dependence on government contracts and delays in its Neutron rocket program. Rocket Lab will report Q4 and full-year results on Feb. 26.
Rocket Lab stock price drops 6.6% and hangs near $80 after the bell — what to watch c

Rocket Lab stock price drops 6.6% and hangs near $80 after the bell — what to watch c

Rocket Lab shares fell 6.55% Friday to $80.07 before stabilizing near $80 in after-hours trading. The drop followed the company’s 81st Electron launch, sending NEONSAT-1A into orbit. Investors await the Feb. 26 earnings report for updates on the delayed Neutron rocket, after a Stage 1 tank rupture during testing. Broader markets also slid after Trump named Kevin Warsh as Fed pick and inflation data beat forecasts.
31 January 2026
Rocket Lab stock price falls as RKLB slips on Neutron schedule focus ahead of Feb. 26 results

Rocket Lab stock price falls as RKLB slips on Neutron schedule focus ahead of Feb. 26 results

Rocket Lab shares fell 3.1% to $85.84 as the Nasdaq dropped 1.4% Thursday afternoon. Investors tracked the arrival of Neutron’s “Hungry Hippo” hardware in Virginia and awaited a Feb. 26 earnings update for new launch timing. The company is reviewing a recent Stage 1 tank rupture that could affect Neutron’s schedule. Implied volatility on Rocket Lab options rose to 97.48, signaling expectations of sharp price swings.
Rocket Lab stock jumps, but Neutron setback keeps investors on edge ahead of February results

Rocket Lab stock jumps, but Neutron setback keeps investors on edge ahead of February results

Rocket Lab shares rose 8% Tuesday before slipping after hours, following a recent Neutron Stage 1 tank rupture that cast uncertainty on the rocket’s launch timeline. The stock traded near $87, up from $80.48, after rebounding from a 9.5% drop Monday. Investors await the late-February earnings call for updates on the Neutron program. The company also secured an $816 million U.S. defense contract.
Rocket Lab stock jumps on “Hungry Hippo” Neutron fairing delivery as Feb. 26 earnings loom

Rocket Lab stock jumps on “Hungry Hippo” Neutron fairing delivery as Feb. 26 earnings loom

Rocket Lab shares rose 5.7% to $85.06 Tuesday after the company announced its “Hungry Hippo” Neutron rocket fairing arrived at Wallops Island, Virginia. The stock rebounded from a nearly 10% drop the previous day. Investors remain focused on Neutron’s first-flight timeline after a recent tank rupture during testing. Rocket Lab will report earnings after markets close on Feb. 26.
Rocket Lab stock price slides as Neutron tank rupture clouds 2026 launch plans

Rocket Lab stock price slides as Neutron tank rupture clouds 2026 launch plans

Rocket Lab shares fell 6.6% to $83.06 by midday Monday after a first-stage tank ruptured during Neutron rocket testing. The company is reviewing test data and will update its launch schedule during its February earnings call. Shares remain up 26% year-to-date despite the setback. Investors are watching for delays to Neutron’s debut, originally targeted for early 2026.
Rocket Lab stock price today: RKLB slips after hours as Neutron tank test rupture keeps timeline in focus

Rocket Lab stock price today: RKLB slips after hours as Neutron tank test rupture keeps timeline in focus

Rocket Lab shares closed up 1.1% at $88.90 Friday, then slipped 0.4% after hours following news of a Stage 1 tank rupture during Neutron rocket testing. The company is assessing possible schedule impacts. Earlier, Rocket Lab completed its first Electron launch of 2026 and plans another mission next week. Director Jon Olson sold 15,205 shares on Jan. 20 under a pre-arranged plan.
Rocket Lab stock rebounds as Neutron test rupture hangs over 2026 debut

Rocket Lab stock rebounds as Neutron test rupture hangs over 2026 debut

Rocket Lab shares rose 3.1% to $90.72 by late Friday morning after a Stage 1 tank rupture during Neutron rocket testing raised concerns about launch delays. The company is reviewing test data to assess impacts on its schedule, with an update expected during its February earnings call. Director Jon A. Olson sold 15,205 shares on Jan. 20, retaining 345,630. Rocket Lab completed its 80th Electron launch this week.
1 2 3 5

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:10 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Go toTop